TCR therapy (T-cell receptor engineered T cells)

01Overview and value chain#

Markers EC: ATMP Regulation (EC No 1394/2007) + FDA cell-therapy guidance | OECD: Bio-pharma | Regulator: FDA (USA), EMA (European Union), NMPA (China)

TCR therapy engineers a patient’s T cells with a high-affinity T-cell receptor (TCR) that recognises an intracellular tumour peptide presented on HLA — a target class that CAR-T (which sees surface antigens) cannot reach. Adaptimmune’s Tecelra (afamitresgene autoleucel) was the first TCR-T approved, targeting MAGE-A4 in synovial sarcoma, and Immunocore’s Kimmtrak (tebentafusp), a soluble TCR-bispecific against gp100, was shown in April 2026 to double the likelihood of being alive at five years in metastatic uveal melanoma. Lyell Immunopharma reported a June 2026 safety update on LYL273 in relapsed solid tumours, TScan Therapeutics is building a TCR-T discovery and treatment platform (Nasdaq: TCRX, Q1 2026), and Medigene’s MDG1015 is a first-in-class, third-generation TCR construct. The field is the engineered-T-cell answer to solid tumours.

The key directions of TCR therapy are:

1. Autologous TCR-T cell therapy (TCR-T): patient T cells transduced with an affinity-enhanced TCR against an intracellular peptide-MHC target — Adaptimmune (Tecelra, MAGE-A4), Lyell (LYL273), TScan, Medigene (MDG1015).
2. Soluble TCR bispecifics (TCR Bispecific): a fused TCR-anti-CD3 molecule that recruits polyclonal T cells to a tumour peptide-MHC — Immunocore (Kimmtrak/tebentafusp, gp100).
3. TCR discovery and target selection (TCR Discovery): high-throughput identification of tumour-specific peptide-MHC targets (MAGE-A4, NY-ESO-1, gp100, PRAME) and of high-affinity, HLA-restricted TCRs (e.g. HLA-A*02:01).
4. Solid-tumour durability and manufacturing (Solid Tumour): epigenetic reprogramming to resist T-cell exhaustion (Lyell) and point-of-care manufacturing to shorten vein-to-vein time.

Sectoral value chain#

[tumour peptide-MHC target] ──> [high-affinity TCR isolation + lentiviral vector] ──> [engineered TCR-T product]
                                              │
                                     (lymphodepletion conditioning)
                                              │
                                              ▼
[solid-tumour response] <─── [TCR-T infusion + immune management] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• HLA-restricted peptide-MHC targeting (MHC Restriction): TCRs recognise intracellular peptides presented on HLA (e.g. HLA-A*02:01), which is what lets TCR therapy reach solid-tumour targets CAR-T cannot, but also ties each product to a patient’s HLA type.
• Lentiviral TCR delivery (Lentiviral Vector): TCR alpha and beta chains are delivered via integrating lentiviral vector, with engineered cysteine modifications to enforce correct pairing and avoid mis-pairing with the endogenous TCR.
• Soluble TCR bispecifics (TCR Bispecific): Immunocore’s Kimmtrak fuses an affinity-enhanced TCR to an anti-CD3 scFv, turning the TCR into an off-the-shelf drug that recruits polyclonal T cells.

02US#

The US hosts Lyell Immunopharma and TScan Therapeutics, and the FDA approved the first TCR-T product.

Lyell, TScan, FDA#

• Lyell Immunopharma (Nasdaq: LYEL): a late-stage clinical company advancing next-generation chimeric antigen receptor and TCR-T cell therapies, with a June 2026 safety update on LYL273 in relapsed solid tumours; its epigenetic reprogramming technology addresses T-cell exhaustion, the central obstacle in solid-tumour cell therapy.
• TScan Therapeutics (Nasdaq: TCRX): a clinical-stage biotechnology company building a TCR discovery and TCR-T treatment platform, reporting first-quarter 2026 financials in May 2026; it identifies tumour-specific targets via T-cell receptor sequencing.
• FDA framework: TCR-T products are approved as biologics / ATMPs with risk evaluation and mitigation strategies; the first TCR-T approval (Tecelra, 2024) established the regulatory pathway for HLA-restricted personalised cell therapy.

03CN#

China’s TCR-T field is emerging and largely pre-commercial, with academic and early-stage biotech activity rather than a marketed product.

emerging TCR-T, NMPA, academic#

• Emerging pre-commercial field: enrichment returned blog and academic coverage rather than a source-confirmed commercial Chinese TCR-T product, so the CN block is treated qualitatively; domestic activity is early-stage.
• NMPA pathway: TCR-T candidates enter clinical development under the NMPA cell-therapy framework, behind the US/EU leaders but within China’s broader cell-therapy investment wave.
• Solid-tumour rationale: China’s large solid-tumour burden underpins interest in TCR-T, which — unlike CAR-T — can target intracellular tumour antigens presented on HLA.

04EU#

Europe is the origin of both approved TCR products — Adaptimmune and Immunocore are UK-based — plus Medigene’s TCR pipeline.

Adaptimmune, Immunocore, Medigene, EMA#

• Adaptimmune (United Kingdom): its TCR-T product Tecelra (afamitresgene autoleucel) targets MAGE-A4 in synovial sarcoma and was the first engineered-TCR cell therapy approved, anchoring the autologous TCR-T class alongside pipeline assets lete-cel (NY-ESO-1) and other MAGE-A4/PRAME programmes.
• Immunocore (United Kingdom): Kimmtrak (tebentafusp), a soluble gp100 TCR-anti-CD3 bispecific for HLA-A*02:01+ metastatic uveal melanoma, was reported in April 2026 to double the likelihood of being alive at five years — the first TCR-based bispecific approved.
• Medigene (Germany): MDG1015 is a first-in-class, third-generation TCR construct, with the company’s broader pipeline (MDG3020, MDG3010) extending its TCR platform.
• EMA framework: TCR therapies are advanced therapy medicinal products centrally authorised by the European Medicines Agency under Regulation (EC) No 1394/2007.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack pairs high-affinity TCR discovery with chain-engineered lentiviral delivery, autologous GMP manufacturing, and — for the bispecific variant — a soluble TCR that recruits polyclonal T cells.

1. Autologous TCR-T (TCR-T):
   • Adaptimmune’s Tecelra (afamitresgene autoleucel) is the first approved TCR-T, targeting MAGE-A4 in synovial sarcoma; Lyell’s LYL273 (June 2026 safety update) and Medigene’s MDG1015 (third-generation TCR) extend the autologous class.
   • Lyell’s epigenetic reprogramming directly addresses T-cell exhaustion, the central reason engineered T cells fail in solid tumours.
2. Soluble TCR bispecifics (TCR Bispecific):
   • Immunocore’s Kimmtrak (tebentafusp) fuses an affinity-enhanced gp100 TCR to an anti-CD3 scFv, and was shown in April 2026 to double five-year survival in HLA-A*02:01+ metastatic uveal melanoma.
   • The bispecific format converts the TCR from a cell-bound receptor into an off-the-shelf drug that redirects the patient’s existing T cells.
3. TCR discovery and targeting (TCR Discovery):
   • TScan Therapeutics uses T-cell receptor sequencing to identify tumour-specific peptide-MHC targets and the TCRs that recognise them, feeding a pipeline across MAGE-A4, NY-ESO-1, gp100 and PRAME.
   • HLA restriction (e.g. HLA-A*02:01) is the defining constraint — and the opportunity — that lets TCR therapy reach intracellular tumour antigens.

07Value chains and production pipelines#

Industrial pipeline of an autologous TCR-T product (ATMP Regulation, HLA-restricted)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Antigen & TCR          │ ───> │ 2. TCR engineering &      │
│    discovery              │      │    vector production      │
└───────────────────────────┘      └───────────────────────────┘
                                                   │
                                                   ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Lymphodepletion        │ <─── │ 3. Autologous cell        │
│                           │      │    manufacturing          │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Infusion & monitoring  │ ───> │ 6. Follow-up & PV         │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Antigen and TCR discovery

Tumour-specific intracellular antigens (MAGE-A4, NY-ESO-1, gp100, PRAME) are identified, their peptide-MHC presentation characterised, and high-affinity, HLA-restricted TCRs (e.g. HLA-A*02:01) isolated by high-throughput screening (TScan platform).

Stage 2: TCR engineering and vector production

The selected TCR alpha and beta chains are cloned, affinity-matured and engineered with cysteine modifications to enforce correct pairing and avoid mis-pairing with the endogenous TCR, then packaged in a lentiviral vector.

Stage 3: Autologous cell manufacturing

The patient’s T cells are transduced with the TCR lentiviral vector, expanded in closed GMP systems, and released as a cryopreserved TCR-T product, tied to the patient’s HLA type.

Stage 4: Lymphodepletion

The patient receives lymphodepleting chemotherapy to create immunological space for TCR-T expansion and persistence in the solid-tumour microenvironment.

Stage 5: Infusion and monitoring

The TCR-T product is re-infused and the patient is monitored for immune toxicity (cytokine release, on-target/off-tumour effects against normal MAGE-A4-positive tissues) and early response.

Stage 6: Follow-up and pharmacovigilance

Long-term follow-up tracks TCR-T persistence, durability of solid-tumour response and late toxicities, feeding the pharmacovigilance record that supports the still-young TCR-T class.